GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arbutus Biopharma Corp (FRA:I9DN) » Definitions » YoY EBITDA Growth

Arbutus Biopharma (FRA:I9DN) YoY EBITDA Growth : -27.17% (As of Mar. 2025)


View and export this data going back to 2014. Start your Free Trial

What is Arbutus Biopharma YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Arbutus Biopharma's YoY EBITDA Growth for the quarter that ended in Mar. 2025 was -27.17%.

Arbutus Biopharma's EBITDA per Share for the three months ended in Mar. 2025 was €-0.12.


Arbutus Biopharma YoY EBITDA Growth Historical Data

The historical data trend for Arbutus Biopharma's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arbutus Biopharma YoY EBITDA Growth Chart

Arbutus Biopharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 75.53 4.63 35.18 -1.29 10.20

Arbutus Biopharma Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.10 -4.35 16.36 40.78 -27.17

Arbutus Biopharma YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Arbutus Biopharma's YoY EBITDA Growth for the fiscal year that ended in Dec. 2024 is calculated as:

YoY EBITDA Growth (A: Dec. 2024 )
=(EBITDA per Share (A: Dec. 2024 )-EBITDA per Share (A: Dec. 2023 ))/ | EBITDA per Share (A: Dec. 2023 ) |
=(-0.352--0.392)/ | -0.392 |
=10.20 %

Arbutus Biopharma's YoY EBITDA Growth for the quarter that ended in Mar. 2025 is calculated as:

YoY EBITDA Growth (Q: Mar. 2025 )
=(EBITDA per Share (Q: Mar. 2025 )-EBITDA per Share (Q: Mar. 2024 )) / | EBITDA per Share (Q: Mar. 2024 )) |
=(-0.117--0.092)/ | -0.092 |
=-27.17 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Arbutus Biopharma YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Arbutus Biopharma's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Arbutus Biopharma Business Description

Traded in Other Exchanges
Address
701 Veterans Circle, Warminster, PA, USA, 18974
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Arbutus Biopharma Headlines

No Headlines